NEW YORK (GenomeWeb) – The New York State Department of Health has approved BioTheranostics to offer its Breast Cancer Index to residents in the state, the company said today.

The molecular diagnostic test quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer. According to the San Diego firm, it is the only commercially available biomarker for estrogen receptor-positive breast cancer patients that accurately predicts early and late distant recurrence of the disease while also predicting the benefit from extended endocrine therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.